Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

被引：0

作者：

Masashi Niwakawa

Katsuyoshi Hashine

Raizo Yamaguchi

Hirofumi Fujii

Yasuo Hamamoto

Koichi Fukino

Takahiko Tanigawa

Yoshiteru Sumiyoshi

机构：

[1] Division of Urology,Department of Urology

[2] Shizuoka Cancer Center Hospital,Division of Clinical Oncology

[3] National Hospital Organization,Department of Medical Oncology

[4] Shikoku Cancer Center,Department of Urology

[5] Jichi Medical University,undefined

[6] Tochigi Cancer Center Hospital,undefined

[7] Bayer Yakuhin,undefined

[8] Ltd.,undefined

[9] Teikyo University School of Medicine,undefined

来源：

Investigational New Drugs | 2012年 / 30卷 / 3期

关键词：

D O I：

10.1007/s10637-011-9771-9

中图分类号：

学科分类号：

摘要：

引用

页码：1274 / 1275

页数：1

共 50 条

[21] Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics
David Z. Chang
Thomas Olencki
Thomas G. Budd
David Peereboom
R. Ganapathi
Bruno Osterwalder
Ronald Bukowski
Cancer Chemotherapy and Pharmacology, 2001, 48 : 493 - 498
[22] IMMUNOLOGICAL EFFECTS OF TREATMENT WITH SEQUENTIAL ADMINISTRATION OF RECOMBINANT INTERFERON-GAMMA AND INTERFERON-ALPHA IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA DURING A PHASE-I TRIAL
ERNSTOFF, MS
GOODING, W
NAIR, S
BAHNSON, RR
MIKETIC, LM
BANNER, B
DAY, R
WHITESIDE, T
TITUSERNSTOFF, L
KIRKWOOD, JM
CANCER RESEARCH, 1992, 52 (04) : 851 - 856
[23] Phase II study of interferon-alpha (IFN), Gleevec or Iressa patients with metastatic renal cell carcinoma.
Amato, R
Kareidy, M
Marsh, L
Truong, L
Shen, S
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9030S - 9030S
[24] The Impact of Combination Therapy of Sunitinib with Interferon-Alpha on Survival of Patients with Loco Regional and Metastatic Clear Renal Cell Carcinoma
Aznab, Mozaffar
Rezaei, Mansour
INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (10)
[25] Capecitabine in combination with interferon-alpha in interleukin-2-refractory metastatic renal cell carcinoma (MRCC)
Demidov, L. V.
Tsimafeyeu, I. V.
Naidzionak, U. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
Ellerhorst, JA
Sella, A
Amato, RJ
Tu, SM
Millikan, RE
Finn, LD
Banks, M
Logothetis, CJ
CANCER, 1997, 80 (11) : 2128 - 2132
[27] A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients
Oh, WK
Manola, J
George, DJ
Fierman, A
Fontaine-Rothe, P
Morrissey, S
Prisby, J
Kaufman, DS
Shapiro, CL
Kantoff, PW
Smith, MR
CANCER INVESTIGATION, 2002, 20 (02) : 186 - 191
[28] Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
Rini, B. I.
Halabi, S.
Rosenberg, J.
Stadler, W. M.
Vaena, D. A.
Atkins, J. N.
Picus, J.
Czaykowski, P.
Dutcher, J.
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[29] Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
Rini, B. I.
Halabi, S.
Rosenberg, J.
Stadler, W. M.
Vaena, D. A.
Atkins, J. N.
Picus, J.
Czaykowski, P.
Dutcher, J.
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[30] Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma
Schreeder, M. T.
Figlin, R. A.
Stephenson, J. J.
Campos, L.
Chawla, S. P.
Spigel, D. R.
Spira, A.
Sportelli, P.
Gardner, L.
Birch, R.
Henderson, I. C.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →